Background Tumor Treating Fields (TTFields) are a non-invasive, antiangiogenic cancer therapy. The Phase 2 INNOVATE study demonstrated safety of TTFields/weekly paclitaxel in 31 PROC (platinum-resistant ovarian cancer) patients (Vergote Gyn Onc 2018); efficacy: median PFS 8.9 months, 25% partial response, 71% clinical benefit and 61% 1-year survival rate. This phase 3 ENGOT-ov50/GOG-329/INNOVATE-3 study [NCT03940196] investigates TTFields plus weekly paclitaxel in PROC patients.

Study Design Patients (N=540) will have PROC (RECIST V1.1) within 6 months of last platinum therapy with maximum of 2-5 prior lines of systemic therapy, ECOG 0-1 and no peripheral neuropathy >grade 1. Patients with primary refractory disease will be excluded. Patients will be randomized 1:1 to weekly paclitaxel alone or weekly paclitaxel (starting of dose 80 mg/m2 weekly for 8 weeks, and then on Days 1, 8, and 15 for subsequent 28-day cycle) plus TTFields (200 kHz for 18 hours/day and continued if no progression in the abdominal or pelvic regions (‘in-field region’) per RECIST V1.1. Clinical follow-up will be performed q4w, with radiological follow-up (CT or MRI scans of the abdomen and chest) q8w. The primary endpoint is overall survival. Secondary endpoints: PFS, objective response rate, AEs, and quality of life (EORTC QLQ-C30 with QLQ-OV28). Sample size (n=540) will detect an increase in median OS from 12 to 16 months (HR 0.75). Data Monitoring Committee (DMC) meeting (March 2020) concluded that data to-date showed no safety issues and recommended trial continuation.

Mortality Trends in Gynecological Cancers in Chile

Introduction Gynecologic cancers account for an important number of deaths in women in Chile. Substantial efforts have been made over the last 20 years to improve access to healthcare to reduce cancer mortality.

Objective To evaluate gynecologic cancer mortality trends during the last 21 years in Chile.

Methods Cause-of-death figures were obtained from 1996 until 2017. Age-adjusted mortality rate was calculated for each gynecologic cancer, using the 2017 census data as the standard population. Logistic regression model was utilized to determine trends, confidence interval and reveal changes in tendencies if occurred.

Results Three of the four studied cancers showed a significant reduction in mortality rates. There was a sustained reduction, although modest, in breast and ovarian cancer mortality of 0.77% (CI -1.0 to -0.6) and 0.63% (CI -1.1 to -0.2) per year, respectively. The most significant change was observed in cervical cancer with an annual reduction of 4% (CI -4.3 to -3.7). All corpus uteri cancers considered together, had a non-significant tendency towards reduction. In a subanalysis of mortality for cervical cancer in women under 40 years, we observed a break in the negative tendency after 2011, revealing a rise of 5.1% (CI -0.6 to 11.2) per year.

Conclusion There was a reduction in mortality rate in most of the studied cancers. Although cervical cancer showed the most important reduction trend, is still far from the lowest figures published in the literature. The change in tendency for the younger population with cervical cancer is of concern.
mass and prognosis of elderly epithelial ovarian cancer patients has not been clarified. This study aimed to evaluate association between iliopsoas muscle mass and prognosis of elderly ovarian cancer patients in the Japanese population.

**Method** Medical charts of 110 epithelial ovarian cancers aged 60 years and older at our hospitals between 2013 and 2014 were retrospectively reviewed. Muscle areas of bilateral psoas major muscles at the third lumbar vertebra were measured using images obtained by computed tomography tested before treatment. Psoas muscle index (PMI) was calculated as the psoas muscle area divided by the height squared. Cox-regression Hazard Models were applied.

**Results** Median follow-up period was 40 months, average age was 67.8 years, and median PMI was 313 mm²/m² (range 137–572). 44 patients (40.0%) with less than 300 mm²/m² PMI were found to be statistically poor prognosis in multivariate analysis (Hazard Ratio: 2.896, 95% Confidence Interval: 1.1510–7.287, P value: 0.024).

**Conclusions** Low PMI was a statistically significant poor prognostic factor in Japanese elderly patients with epithelial ovarian cancer. It suggests that low PMI can be a biomarker that predicts poor prognosis in elderly patients with epithelial ovarian cancer.

**IGCS20_1389**

**A RETROSPECTIVE COHORT STUDY FOR FEASIBILITY OF LAPAROSCOPIC HYSTERECTOMY IN PATIENTS WITH STAGE IA1 CERVICAL CANCER**

R Yamada*, Y Todo, H Matsumiya, H Kurosu, K Minowa, T Tsuruta, S Minobe, H Kato. Hokkaido Cancer Center, Japan

10.1136/ijgc-2020-IGCS.313

**Objective** The objective of this study was to verify the feasibility of laparoscopic hysterectomy in patients with stage IA1 cervical cancer.

**Methods** This retrospective study was carried out using data for 103 patients with stage IA1 cervical cancer at Hokkaido Cancer Center from January 2000 to December 2016. Study outcomes including operation time, estimated blood loss, blood transfusion, recurrence, and survival were compared between conization group (n=36) and hysterectomy group (n=67). Among patients in the hysterectomy group, those outcomes were compared between non-laparoscopic hysterectomy group (n=31) and laparoscopic hysterectomy group (n=36).

**Results** In the present study, there was only one patient with cancer recurrence who underwent cervical conization. The rate of cases of cancer recurrence in the conization group tended to be higher than in the hysterectomy group (2.8% vs. 0%, P=0.18). Estimated blood loss in the laparoscopic hysterectomy group was significantly less than in the non-laparoscopic group (213 g vs. 46.5 g, P=0.0017). The rate of patients who received blood transfusion in the laparoscopic hysterectomy group tended to be higher than in the non-laparoscopic group (9.7% vs. 0%, P=0.056).

**Conclusion** It is highly possible that laparoscopic hysterectomy is a safe operative procedure in stage IA1 cervical cancer when performed by experienced surgeons in tertiary centers.

**IGCS20_1390**

**MANAGEMENT OF BENIGN METASTASIZING LEIOMYOMA: A REPORT OF THREE CASES**

K Inoue*, M Yamaguchi, T Ueda, R Isono, Y Takimoto, H Tsutamoto, H Shibahara. Hyogo College of Medicine, Japan

10.1136/ijgc-2020-IGCS.314

Benign metastasizing leiomyoma (BML) is a rare disease associated with a history of uterine surgery leiomyomas. BML is often seen in the lungs. Symptomatic patients with BML are usually treated with surgical resection or medical castration. Here, we report three patients diagnosed with BML. A 58-year-old patient presented with back pain. Magnetic resonance imaging (MRI) and positron emission tomography (PET/CT) showed a tumor of 3 cm in diameter in the L2/L3 vertebral with Fluorine-18 deoxyglucose (FDG) accumulation. Histopathology of CT-guided biopsy was